Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes

Author:

Gras Emmanuelle12ORCID,Aiello Tommaso Francesco13,Chumbita Mariana1,Gallardo-Pizarro Antonio13,Monzó-Gallo Patricia13,Teijón-Lumbreras Christian1,Suárez-Lledó Maria4,Magnano Laura4,Tuset Montse5,Marcos Maria Ángeles6,Soriano Alex137ORCID,Garcia-Vidal Carolina137ORCID

Affiliation:

1. Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona , Carrer de Villarroel 170, 08036 Barcelona , Spain

2. Sorbonne Université, INSERM, Institut Pierre Louis d’Épidémiologie et de Santé Publique , F75012 Paris , France

3. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), c. Casanova, 143 , 08036 Barcelona , Spain

4. Department of Hematology, Division of Medicines, Hospital Clínic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain

5. Department of Pharmacy, Division of Medicines, Hospital Clínic Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , Barcelona , Spain

6. Department of Microbiology, Hospital Clinic, Universitat de Barcelona, ISGlobal , Barcelona , Spain

7. Center for Biomedical Research in the Infectious Diseases Network (CIBER) , Barcelona , Spain

Abstract

Abstract Objectives To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined. Methods We conducted a retrospective evaluation of our prospectively followed cohort of haematological patients treated with remdesivir for more than 10 days. Starting January 2023, upon COVID-19 diagnosis, the treatment strategy was based on symptoms and PCR cycle threshold (Ct) as follows: (i) when Ct was 25 or less or if the patient had symptoms, a course of remdesivir for at least 10 days, nirmatrelvir/ritonavir for 5 days (whenever possible) and convalescent plasma was administered; and (ii) when the patient was asymptomatic and had a PCR Ct of more than 25, when possible, a course of 5 days of nirmatrelvir/ritonavir was administered. The patient was considered to have achieved viral clearance and, thus, remdesivir was stopped, in either of these cases: (i) PCR negativity, or (ii) subgenomic RNA negativity. Results From January to November 2023, 18 patients benefited from a safe extended remdesivir administration, resulting in detection of SARS-CoV-2 viral clearance in a median time of 3.5 weeks (IQR 2.6–3.9) (min–max 1.6–8.0). No clinical or biological side effects were detected. No patient died or needed further treatment for their COVID-19 episode. Conclusions The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.

Funder

Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III

Instituto de Salud Carlos III

Resolución de la Dirección del Instituto de Salud Carlos III, O.A., M.P

European Union

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3